A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.
about
Combined treatment of somatostatin analogues with pegvisomant in acromegalyPegvisomant in acromegaly: an update.Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guidelineExpert consensus document: A consensus on the medical treatment of acromegaly.Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDYLong-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study.Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes.Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour groupPegvisomant: current and potential novel therapeutic applications.Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical ParametersOctreotide long-acting repeatable for acromegaly.Clinical implications of growth hormone-secreting tumor subtypes.Management options for persistent postoperative acromegaly.Investigational therapies for acromegaly.Acromegaly: Beyond surgeryQuality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies.New therapeutic agents for acromegaly.Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.Pasireotide for the treatment of acromegaly.The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.The role of combination medical therapy in the treatment of acromegaly.Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly.Role of the methoxy group in immune responses to mPEG-protein conjugates.Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients.Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly.Pegvisomant and cabergoline combination therapy in acromegaly.Increasing Frequency of Combination Medical Therapy in the Treatment of Acromegaly with the GH Receptor Antagonist Pegvisomant.How to improve effectiveness of pegvisomant treatment in acromegalic patients.
P2860
Q26776366-40E99B29-EA16-4A97-8494-1CEC9AF50F8FQ33725999-A79402E1-4DDD-42ED-83F2-6CB1EB9F39A0Q34277844-EB3E594D-58BC-4448-A84A-315370471D4BQ34406566-2B5CD983-BF8D-4123-B33A-AE0C8E29D2FFQ34446297-F4ED937A-FDC0-48B2-8191-9BAC0A6D73FCQ36119677-DA40188E-E059-4786-ABE8-90F6FF9FEF1AQ36964536-396B3EB5-CA84-40F8-A1DC-7AB49099FAE6Q37629658-3C9969E0-0B55-49FA-BE81-9C94EE360E86Q37633543-8DB42100-2371-4EBB-BEA8-40AF94E36A18Q37678328-DF3E2BE8-B866-45CA-B8A6-03522A41BB32Q37990556-8D125A20-66E7-424C-8392-9F6697F021B1Q37995533-EF2EF5C1-93C5-41ED-BCEC-C0A4629B611EQ38049832-D2045914-96A0-424B-B32C-9A9ACBCDDF5AQ38111437-4ADCDF36-1810-40C5-9B9D-2015DC5FD744Q38130271-4CF0BE4A-D31D-45C1-AC76-A8D4AA4C6372Q38326160-F65EB9AD-83DD-4541-B31B-416BAC5BC38FQ38648739-D87BFC7A-0376-453F-B6E4-9E6B8245EF1DQ38683309-37AFEED4-0DC0-4FFF-9C67-B57062524930Q38710873-24D71F4A-F1E5-415C-8E92-BADFB8764560Q38924730-1062DADE-1549-4EA1-9E29-F6AD2FA52CA4Q38927318-DA708A08-CDD8-49F3-A819-3AC353A27BE8Q39146196-EF73A516-D572-4223-82B4-526093ADCF54Q39687911-9C6EEC91-579E-4CCD-84EE-E1511FD096D0Q41940240-938718AB-E3DE-46BB-BF77-3F6B70692019Q42196860-204E374D-1E73-427F-8E31-F7C415766704Q45065721-B6B2CCE6-50B1-4324-9A69-C736B627058DQ46735065-C8AFA8EA-EBED-4C59-838B-25DA4DA85187Q49681753-4FA9FEB1-7303-4569-AC50-BEB3C088B7D9Q53720920-E2FF85BE-FC88-48E5-9C20-CA8B5F0C716E
P2860
A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
A randomized, controlled, mult ...... e in patients with acromegaly.
@en
A randomized, controlled, mult ...... e in patients with acromegaly.
@nl
type
label
A randomized, controlled, mult ...... e in patients with acromegaly.
@en
A randomized, controlled, mult ...... e in patients with acromegaly.
@nl
prefLabel
A randomized, controlled, mult ...... e in patients with acromegaly.
@en
A randomized, controlled, mult ...... e in patients with acromegaly.
@nl
P2093
P2860
P1476
A randomized, controlled, mult ...... e in patients with acromegaly.
@en
P2093
Christian J Strasburger
Gary Layton
Gwyn A D'Souza
P2860
P304
P356
10.1111/J.1365-2265.2009.03620.X
P577
2009-05-02T00:00:00Z